New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

Palatin Technologies, Inc.

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

 Jan 19, 2023, 07:30 ET  –  BREAKOUT Study is Palatin’s third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists –  Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023 …

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease Read More »

Palatin Receives $4.7 Million of Non-Dilutive Funding

 Jan 18, 2023, 07:30 ET  Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J., Jan. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7 …

Palatin Receives $4.7 Million of Non-Dilutive Funding Read More »

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

 Jan 10, 2023, 07:30 ET  –  Collaboration with The William Harvey Research Institute and Queen Mary University of London –  PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J., Jan. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers …

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions Read More »

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results

 Jan 05, 2023, 07:30 ET  15.4% increase in net product revenue over the prior quarter 1,290% increase over the comparable quarter in 2021 11.5% increase in prescriptions dispensed over the prior quarter Increased 134% over the comparable quarter in 2021 CRANBURY, N.J., January 5, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical …

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results Read More »

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

 Nov 14, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Net Product Revenue Increased 13% and Prescriptions Dispensed Increased 17%, Over the Prior Quarter Prescription Refills Exceed 50% …

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

 Nov 09, 2022, 17:16 ET  CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 Read More »

Palatin Announces $10 Million Registered Direct Offering

 Oct 31, 2022, 09:30 ET  CRANBURY, N.J., Oct. 31, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and …

Palatin Announces $10 Million Registered Direct Offering Read More »

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting

 Oct 24, 2022, 17:32 ET  Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J., Oct. 24, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor …

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting Read More »

First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial

 Oct 20, 2022, 07:30 ET  Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tolerability concerns Primary endpoint is the Mayo Endoscopic Subscore, which evaluates the level of disease in the colon mucosa Interim data currently expected …

First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial Read More »

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)

 Oct 17, 2022, 07:30 ET  Peer-reviewed paper presents notable mechanism of action findings Bremelanotide significantly increased sexual desire for up to 24 hours post administration CRANBURY, NJ, Oct. 17, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor …

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD) Read More »

Scroll to Top